These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 37755647)
21. Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research. Chao HM; Chern E J Formos Med Assoc; 2018 Dec; 117(12):1046-1057. PubMed ID: 30172452 [TBL] [Abstract][Full Text] [Related]
22. Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells. Lin YC; Murayama Y; Hashimoto K; Nakamura Y; Lin CS; Yokoyama KK; Saito S Stem Cell Res Ther; 2014; 5(2):58. PubMed ID: 25157408 [TBL] [Abstract][Full Text] [Related]
23. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency. Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786 [TBL] [Abstract][Full Text] [Related]
24. Advances in the application of induced pluripotent stem cells in pediatric diseases. Tian ZC; Yin XJ Yi Chuan; 2023 Jan; 45(1):42-51. PubMed ID: 36927637 [TBL] [Abstract][Full Text] [Related]
25. Preferential Hematopoietic Differentiation in Induced Pluripotent Stem Cells Derived From Human Umbilical Cord Arterial Endothelial Cells. Pei H; Li H; Xu L; Zhang B; Zhang H; Jia Y; Liang L; Xie X; Fan Z; Yang Z; Wang X; Song F; He L; Yue W; Pei X Arterioscler Thromb Vasc Biol; 2023 May; 43(5):697-712. PubMed ID: 36951064 [TBL] [Abstract][Full Text] [Related]
26. Current understanding and future perspectives of the roles of sirtuins in the reprogramming and differentiation of pluripotent stem cells. Hsu YC; Wu YT; Tsai CL; Wei YH Exp Biol Med (Maywood); 2018 Mar; 243(6):563-575. PubMed ID: 29557214 [TBL] [Abstract][Full Text] [Related]
27. Induced pluripotent stem cells: A new strategy to model human cancer. Bindhya S; Sidhanth C; Shabna A; Krishnapriya S; Garg M; Ganesan TS Int J Biochem Cell Biol; 2019 Feb; 107():62-68. PubMed ID: 30557622 [TBL] [Abstract][Full Text] [Related]
28. Interconversion of Cancer Cells and Induced Pluripotent Stem Cells. Sarker DB; Xue Y; Mahmud F; Jocelyn JA; Sang QA Cells; 2024 Jan; 13(2):. PubMed ID: 38247819 [TBL] [Abstract][Full Text] [Related]
29. Advances in the Application of Induced Pluripotent Stem Cells in Alzheimer's Disease and Parkinson's Disease. Xu Y; Wang S; Zhu P Curr Stem Cell Res Ther; 2023; 18(2):154-162. PubMed ID: 35473516 [TBL] [Abstract][Full Text] [Related]
30. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy. Zhang G; Shang B; Yang P; Cao Z; Pan Y; Zhou Q Stem Cells Dev; 2012 Apr; 21(6):955-64. PubMed ID: 22185567 [TBL] [Abstract][Full Text] [Related]
31. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges. Lu F; Ma XJ; Jin WL; Luo Y; Li X Front Immunol; 2021; 12():690565. PubMed ID: 34054880 [TBL] [Abstract][Full Text] [Related]
32. Induced pluripotent stem cell line (PEIi003-A) derived from an apparently healthy male individual. Fuchs NV; Schieck M; Neuenkirch M; Tondera C; Schmitz H; Steinemann D; Göhring G; König R Stem Cell Res; 2020 Jan; 42():101679. PubMed ID: 31837633 [TBL] [Abstract][Full Text] [Related]
33. Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications. Das AK; Pal R J Tissue Eng Regen Med; 2010 Aug; 4(6):413-21. PubMed ID: 20084623 [TBL] [Abstract][Full Text] [Related]
34. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Choi SM; Liu H; Chaudhari P; Kim Y; Cheng L; Feng J; Sharkis S; Ye Z; Jang YY Blood; 2011 Aug; 118(7):1801-5. PubMed ID: 21628406 [TBL] [Abstract][Full Text] [Related]
35. Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers. Turhan A; Foudi A; Hwang JW; Desterke C; Griscelli F; Bennaceur-Griscelli A Exp Hematol; 2019 Mar; 71():61-67. PubMed ID: 30659851 [TBL] [Abstract][Full Text] [Related]
36. Perspectives for induced pluripotent stem cell technology: new insights into human physiology involved in somatic mosaicism. Nagata N; Yamanaka S Circ Res; 2014 Jan; 114(3):505-10. PubMed ID: 24481841 [TBL] [Abstract][Full Text] [Related]
37. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions. Lupo KB; Moon JI; Chambers AM; Matosevic S Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175 [TBL] [Abstract][Full Text] [Related]
38. iPSCs Derived from Malignant Tumor Cells: Potential Application for Cancer Research. Cheng H; Liu C; Cai X; Lu Y; Xu Y; Yu X Curr Stem Cell Res Ther; 2016; 11(5):444-50. PubMed ID: 26899393 [TBL] [Abstract][Full Text] [Related]
39. A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Moad M; Pal D; Hepburn AC; Williamson SC; Wilson L; Lako M; Armstrong L; Hayward SW; Franco OE; Cates JM; Fordham SE; Przyborski S; Carr-Wilkinson J; Robson CN; Heer R Eur Urol; 2013 Nov; 64(5):753-61. PubMed ID: 23582880 [TBL] [Abstract][Full Text] [Related]